Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 2022

View Archived Issues

New animal models reveal potential topical therapies for congenital nevi

RGS16 impacts CD8+ T-cell exhaustion and limits therapy efficacy

New Rho kinase 2 inhibitors identified at Medshine Discovery

Hongyun Biotech presents new MAP4K1 inhibitors

Guangzhou Henovcom Bioscience discovers autotaxin inhibitors

New lysophosphatidic acid receptor 1 antagonists patented by Humanwell Healthcare

RIKEN presents new immunostimulants

Tau-targeting therapy reduces epilepsy and autism behaviors in model of Dravet syndrome

FDA accepts IND for novel oral immune checkpoint inhibitor, TT-816

Chimeric switch-receptor PD1-DAP10-41BB augments NK92 cell antitumor activity

SHH expression is required for bone regeneration in a murine model

Long in the making changes lead to tipping point in blood stem cells

MARCH8 attenuates cGAS-mediated innate autoimmune responses

Nitrase Therapeutics announces expansion of pipeline to include oncology programs

Janux Therapeutics' JANX-007 to advance into clinical development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...